Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis

No abstract is available for this paper.

• Publication year

  2005

• Venue

  NeuroReport

• Publication date

  2005-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00001756-200503150-00003PMID 15729130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matrix Metalloproteinase-9 Is Required for Adequate Angiogenic Revascularization of Ischemic Tissues: Potential Role in Capillary Branching

  2004cited by this paper
• Unraveling the mechanisms involved in motor neuron degeneration in ALS.

  2004cited by this paper
• Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study.

  2004cited by this paper
• Kainic acid-mediated upregulation of matrix metalloproteinase-9 promotes retinal degeneration.

  2004cited by this paper
• Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue

  2004cited by this paper
• Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease.

  2003cited by this paper
• Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression.

  2003cited by this paper
• Minocycline delays disease onset and mortality in a transgenic model of ALS

  2002cited by this paper
• Gelatinase B deficiency protects against endotoxin shock

  2002cited by this paper
• S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death

  2002cited by this paper
• Protective effect of parvalbumin on excitotoxic motor neuron death.

  2002cited by this paper
• Extracellular proteases and neuronal cell death.

  2002cited by this paper
• Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9)

  2002cited by this paper
• Immune reactivity in a mouse model of familial ALS correlates with disease progression

  2001cited by this paper
• Metalloproteinases in biology and pathology of the nervous system

  2001cited by this paper
• Matrix metalloproteinase‐9 is elevated in serum of patients with amyotrophic lateral sclerosis

  2000cited by this paper
• Induction of Matrix Metalloproteinase MMP‐9 (92‐kDa Gelatinase) by Retinoic Acid in Human Neuroblastoma SKNBE Cells

  2000cited by this paper
• Role for Matrix Metalloproteinase 9 after Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94

  2000cited by this paper
• Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions.

  1999cited by this paper
• Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas

  1999cited by this paper
• Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.

  1998cited by this paper
• Matrix Metalloproteinases in the Neocortex and Spinal Cord of Amyotrophic Lateral Sclerosis Patients

  1996cited by this paper
• The Expression of Tissue‐type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis: Comparison of Stages in Lesion Evolution

  1996cited by this paper
• A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis.

  1994cited by this paper

• Neutrophils: a subgroup of neglected immune cells in ALS

  2023cites this paper
• Metalloproteinases and their tissue inhibitors in Alzheimer’s disease and other neurodegenerative disorders

  2019cites this paper
• Matrix metalloproteinases in the CNS: interferons get nervous

  2019cites this paper
• The Role of Matrix Metalloproteinases in Neurovascular Unit Integrity in Amyotrophic Lateral Sclerosis

  2017cites this paper
• MMP-9 inhibition facilitates amacrine cell loss after ouabain-induced retinal damage.

  2015cites this paper
• Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex.

  2015cites this paper
• A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies

  2015cites this paper
• Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration.

  2014cites this paper
• Metal complexes and metalloproteases: targeting conformational diseases.

  2014cites this paper
• Using the natural resistance of motor neuron subpopulations to identify therapeutic targets in amyotrophic lateral sclerosis

  2014influential citation
• Monitoring the biomolecular interactions and the activity of Zn-containing enzymes involved in conformational diseases: experimental methods for therapeutic purposes.

  2014cites this paper
• Death Receptors in the Selective Degeneration of Motoneurons in Amyotrophic Lateral Sclerosis

  2013cites this paper
• Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade

  2013influential citation
• Microglial Cell Activation is a Source of Metalloproteinase Generation during Hemorrhagic Transformation

  2012cites this paper
• Secretion of Matrix Metalloproteinase-9 from Astrocytes by Inhibition of Tonic P2Y14-Receptor-Mediated Signal(s)

  2012cites this paper
• ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development.

  2011cites this paper
• Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis

  2011cites this paper
• Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis

  2010cites this paper
• Metalloproteinase alterations in the bone marrow of ALS patients

  2010cites this paper
• Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice.

  2010cites this paper
• The C(-1562)T polymorphism of the MMP-9 gene and the risk of sporadic amyotrophic lateral sclerosis.

  2009cites this paper
• Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

  2008cites this paper
• Signaling by death receptors in the nervous system.

  2008cites this paper
• Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis.

  2007cites this paper
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

  2007cites this paper
• Microglia in amyotrophic lateral sclerosis.

  2007cites this paper
• Matrix metalloproteinases in neuromuscular disease

  2007cites this paper
• MMPs and other matrix-degrading metalloproteinases in neurological disease

  2007cites this paper
• Chapter 19 Therapies in amyotrophic lateral sclerosis: Options for the near and far future.

  2007cites this paper
• The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice.

  2006cites this paper
• Matrix metalloproteinases--a conceptional alternative for disease-modifying strategies in ALS/MND?

  2006cites this paper
• The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice

  2006cites this paper
• Reviews Microglia in Amyotrophic Lateral Sclerosis

  year unknowncites this paper
• Stem Cells and Cloning: Advances and Applications Dovepress Amyotrophic Lateral Sclerosis: Applications of Stem Cells – an Update

  year unknowncites this paper